Regeneron Pharmaceuticals Q2 FY25: where the revenue came from and where it went
The whole income statement of Regeneron Pharmaceuticals for this quarter, as one diagram: what earned the revenue, and what it went on.
- Period
- Apr 1 – Jun 30, 2025
- Reported
- Aug 1, 2025
Revenue$3.68B
+4% year over year
Gross profit$3.14B
85% margin
Operating profit$1.08B
29% margin
Net profit$1.39B
38% margin
Net profit is larger than what operations earned, because the statement adds $0.44B below it, under Other income, net.
The numbers
| Item | Value | Share of revenue | Year over year |
|---|---|---|---|
| Revenue | 3.68 | 100% | +4% |
| Collaboration | 1.86 | 51% | +22% |
| Product | 1.63 | 44% | −15% |
| Service other | 0.18 | 5% | +76% |
| Cost of revenue | −0.54 | 15% | |
| Gross profit | 3.14 | 85% margin | +0pp |
| R&D | −1.42 | 39% | +5pp |
| SG&A | −0.63 | 17% | −4pp |
| Operating profit | 1.08 | 29% margin | −1pp |
| Other income, net | 0.44 | ||
| Tax | −0.13 | ||
| Net profit | 1.39 | 38% margin | −3pp |
236 of 418 companies, most recently reported first
New results in your inbox
When a big company reports, we send you a link to its diagram before anyone has time to comment on it. This is a mailing list, not an account: it does not open the diagrams by itself. No spam, one-click unsubscribe.
Drag or use the arrow keys to see the rest